Detalhe da pesquisa
1.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Haematologica
; 104(11): 2249-2257, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890600
2.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Leuk Lymphoma
; 64(5): 913-926, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255002